Martin Fan
Stock Analyst at Wedbush
(4.93)
# 164
Out of 4,639 analysts
54
Total ratings
87.2%
Success rate
94.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Fan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VOR Vor Biopharma | Maintained: Hold | $18 → $27 | $22.07 | +22.37% | 4 | Aug 12, 2026 | |
| ZURA Zura Bio | Maintained: Buy | $15 → $22 | $5.70 | +285.96% | 4 | Aug 12, 2026 | |
| SANA Sana Biotechnology | Reiterated: Buy | $7 | $3.73 | +87.67% | 5 | Aug 11, 2026 | |
| IMA ImageneBio | Maintained: Sell | $2 | $5.74 | -65.16% | 4 | Aug 6, 2026 | |
| TRAX First Tracks Biotherapeutics | Maintained: Buy | $30 → $60 | $47.23 | +27.04% | 3 | Jul 28, 2026 | |
| RNAC Cartesian Therapeutics | Maintained: Buy | $38 | $8.50 | +347.06% | 6 | Jun 10, 2026 | |
| ARTV Artiva Biotherapeutics | Maintained: Buy | $40 | $11.88 | +236.70% | 3 | May 21, 2026 | |
| FATE Fate Therapeutics | Maintained: Buy | $7 | $2.71 | +158.30% | 4 | May 14, 2026 | |
| NKTR Nektar Therapeutics | Maintained: Hold | $95 → $80 | $75.83 | +5.50% | 3 | May 11, 2026 | |
| ACRS Aclaris Therapeutics | Maintained: Buy | $10 | $5.88 | +70.07% | 7 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $46 | $50.39 | -8.71% | 1 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $42 → $45 | $105.61 | -57.39% | 4 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 | $31.29 | +43.82% | 4 | Dec 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 → $45 | $57.55 | n/a | 2 | Aug 7, 2025 |
Vor Biopharma
Aug 12, 2026
Maintained: Hold
Price Target: $18 → $27
Current: $22.07
Upside: +22.37%
Zura Bio
Aug 12, 2026
Maintained: Buy
Price Target: $15 → $22
Current: $5.70
Upside: +285.96%
Sana Biotechnology
Aug 11, 2026
Reiterated: Buy
Price Target: $7
Current: $3.73
Upside: +87.67%
ImageneBio
Aug 6, 2026
Maintained: Sell
Price Target: $2
Current: $5.74
Upside: -65.16%
First Tracks Biotherapeutics
Jul 28, 2026
Maintained: Buy
Price Target: $30 → $60
Current: $47.23
Upside: +27.04%
Cartesian Therapeutics
Jun 10, 2026
Maintained: Buy
Price Target: $38
Current: $8.50
Upside: +347.06%
Artiva Biotherapeutics
May 21, 2026
Maintained: Buy
Price Target: $40
Current: $11.88
Upside: +236.70%
Fate Therapeutics
May 14, 2026
Maintained: Buy
Price Target: $7
Current: $2.71
Upside: +158.30%
Nektar Therapeutics
May 11, 2026
Maintained: Hold
Price Target: $95 → $80
Current: $75.83
Upside: +5.50%
Aclaris Therapeutics
May 8, 2026
Maintained: Buy
Price Target: $10
Current: $5.88
Upside: +70.07%
Feb 26, 2026
Reiterated: Buy
Price Target: $46
Current: $50.39
Upside: -8.71%
Jan 13, 2026
Maintained: Buy
Price Target: $42 → $45
Current: $105.61
Upside: -57.39%
Dec 22, 2025
Maintained: Buy
Price Target: $45
Current: $31.29
Upside: +43.82%
Aug 7, 2025
Maintained: Buy
Price Target: $40 → $45
Current: $57.55
Upside: n/a